These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 28421342

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The Effect of Selective Retina Therapy for Bevacizumab-Resistant Chronic Central Serous Chorioretinopathy.
    Jeon SH, Kim M, Lee J, Roh YJ.
    Ophthalmologica; 2022; 245(1):91-100. PubMed ID: 34649253
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Selective Retina Therapy in Patients With Chronic Central Serous Chorioretinopathy: A Pilot Study.
    Kang S, Park YG, Kim JR, Seifert E, Theisen-Kunde D, Brinkmann R, Roh YJ.
    Medicine (Baltimore); 2016 Jan; 95(3):e2524. PubMed ID: 26817895
    [Abstract] [Full Text] [Related]

  • 6. The effect of nondamaging subthreshold laser therapy in patients with chronic central serous chorioretinopathy.
    Lee SH, Lee J, Kim M, Roh YJ.
    Graefes Arch Clin Exp Ophthalmol; 2024 May; 262(5):1433-1442. PubMed ID: 38010518
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nondamaging photothermal therapy for the retina: initial clinical experience with chronic central serous retinopathy.
    Lavinsky D, Palanker D.
    Retina; 2015 Feb; 35(2):213-22. PubMed ID: 25158944
    [Abstract] [Full Text] [Related]

  • 10. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
    Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, Kneba M, Grzybowski A.
    BMC Ophthalmol; 2019 Jul 25; 19(1):160. PubMed ID: 31345183
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy.
    Zola M, Daruich A, Matet A, Mantel I, Behar-Cohen F.
    Br J Ophthalmol; 2019 Aug 25; 103(8):1184-1189. PubMed ID: 30355720
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy.
    Oh J, Yoon CK, Kim BH, Yu HG.
    Korean J Ophthalmol; 2021 Feb 25; 35(1):51-63. PubMed ID: 33307626
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Patient characteristics of untreated chronic central serous chorioretinopathy patients with focal versus diffuse leakage.
    van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Blanco-Garavito R, Souied EH, MacLaren RE, Querques G, Fauser S, Hoyng CB, Downes SM, Boon CJF.
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul 25; 257(7):1419-1425. PubMed ID: 31123815
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.